Home  Contact Us
  Follow Us On:
 
Search:
Advertising Advertising Free Newsletter Free E-Newsletter
NEWS

BioNTech and Chinese firm Fosun partner, not Pfizer, to produce vaccine
Published on: 2020-12-14
Share to
User Rating: / 0
PoorBest 

German biotech company BioNTech will be supplying Covid-19 vaccines to Hong Kong from Europe in collaboration with Chinese firm Fosun Pharma, instead of US-Swiss giant Pfizer.
 

Britain became the first Western country to start vaccinating people with an approved vaccine last Tuesday after it granted emergency use authorization for the Pfizer-BioNTech vaccine, made with the new technology mRNA.
 

When Chief Executive Carrie Lam Cheng Yuet-ngor on Friday announced procuring a maximum of 7.5 million doses of vaccine developed by BioNTech in collaboration with mainland biopharmaceutical company Fosun Pharma, she first mentioned Pfizer as a co-supplier.
 

But in a statement that night, the government said Pfizer is BioNTech's partner for vaccines in regions outside China and that the shots to be supplied to Hong Kong will only be in collaboration with Fosun Pharma.
 

Pfizer's absence sparked speculation that the BioNTech shots will be manufactured on the mainland, unlike those supplied to the United States, which are made in Pfizer plants in Michigan and Wisconsin.
 

On Saturday night, the government clarified that the shots to be supplied to Hong Kong will be manufactured in Europe and that the first batch of one million doses is expected to be delivered in the first quarter at the earliest.
 

While Fosun Pharma is responsible for clinical trials, regulatory applications, sales and marketing of the jabs in China, the injections will be provided by BioNTech.

BioNTech has said that its partnership with Pfizer is worldwide, except in China.
 

The German company partnered with the US-Swiss giant Pfizer in research and development of the mRNA-based vaccine, which was funded by the German government.
 

The production of mRNA vaccines requires specialized know-how, in which BioNTech has developed significant expertise in the field over the past 12 years.
 

Producing the vaccines in Europe leads to another question on logistics, as the 95 percent effective BioNTech vaccines must be transported and stored in ultra-cold cargoes of minus-70 degrees Celsius, to which authorities said Fosun has entered discussion with logistics and cold-storage companies, as well as the Airport Authority on necessary arrangements.
 

To get enough vaccines to cover the whole population, the government has secured another 7.5 million shots from Sinovac (Hong Kong) Ltd. They will be produced in Beijing and the first batch of one million will arrive next month at the earliest.
 

辉瑞拒绝向中国提供疫苗?
复星医药已抢占在中国的独家权利!

新冠疫苗上市在即,各药企快马加鞭部署采购分销计划。近日从多位消息人士处获悉,复星医药已开始从航空货运服务商处订购运力,计划从明年1月份开始将BioNTech德国工厂生产的新冠疫苗运往中国,按目前已知的部分运输计划,明年上半年的月均运输量为120万剂,整个上半年的总运输量暂定为720万剂。目前多家航空公司正在为承运该疫苗做准备。
 

对此,复星医药内部人士称,这一数据并不准确。“这可能只是部分物流供应商获得的运力需求,并不是总体的运输量。”
 

11月19日,辉瑞公司和BioNTech公司率先发布全球首个新冠疫苗研发成果,III期临床试验数据显示,其研发的mRNA疫苗BNT162b2对接种人群的保护率达到95%,并未出现与疫苗相关的严重安全问题;另一款由Moderna公司研发的mRNA疫苗也呈现良好效果,III期临床试验结果显示,该疫苗有效性达94.1%,对重症新冠的预防效果则为100%。

该款新冠疫苗在国内的合作伙伴是复星医药。今年3月,复星医药成为BioNTech在中国的战略合作伙伴,共同在中国开发、商业化基于其专有的 mRNA 技术平台研发的、针对新型冠状病毒的疫苗产品。

Comments (0)Add Comment

Write comment

security code
Write the displayed characters


busy
    Subscription    |     Advertising    |     Contact Us    |
Address: Magnetic Plaza, Building A4, 6th Floor, Binshui Xi Dao.
Nankai District. 300381 TIANJIN. PR CHINA
Tel: +86 22 23917700
E-mail: webmaster@businesstianjin.com
Copyright 2024 BusinessTianjin.com. All rights reserved.